These arms report a weight change and do not name ITT or efficacy. They stay out of both estimand sets.
cagrilintide 2.4 mg and semaglutide 2.4 mg · n/r
Obesity, no T2D
Y axis: Change in body weight from baseline, %
0 -5 -10 -15 -20 -25 0 4 8 12 16 20 24 36 48 60 72 Placebo, week 68, -3% Placebo Cagrisema, week 68, -20.4% Cagrisema X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
-20.4% at week 68
REDEFINE 1 · NCT05567796
15 mg · n/r
Obesity, no T2D
Y axis: Change in body weight from baseline, %
0 -5 -10 -15 0 4 8 12 16 20 24 Placebo, week 13, -1.7% Placebo VK2735 15 mg, week 13, -14.7% VK2735 15 mg X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
-14.7% at week 13
VENTURE · NCT06068946
Dose n/r · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
5 0 0 4 8 12 16 20 24 Exenatide once weekly (EQW ), week 24, 3.8% Exenatide once weekly (EQW ) X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
3.8% at week 24
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) · NCT02635386
Dose n/r · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
5 0 0 4 8 12 16 20 24 36 Placebo, week 36, 3.5% Placebo Exenatide once weekly extended-release, week 36, 1.7% Exenatide once weekly extended-release X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
1.7% at week 36
ECHO · NCT02664441
3.0mg · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
5 0 0 4 8 12 16 20 24 36 48 60 Placebo, week 56, 0.28% Placebo Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68), week 56, 0.69% Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68) X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
0.69% at week 56
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes · NCT01272219
3.0mg · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
5 0 0 4 8 12 16 20 24 36 48 60 Placebo, week 56, 0.28% Placebo Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68), week 56, 2.91% Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68) X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
2.91% at week 56
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes · NCT01272219
3.0 mg · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
5 0 -5 0 4 8 12 16 20 24 36 48 60 Placebo, week 56, -0.1% Placebo Lira 3.0 mg, week 56, 2.3% Lira 3.0 mg X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
2.3% at week 56
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes · NCT01272232
Dose n/r · n/r
T2D only
Y axis: Change in body weight from baseline, %
0 -5 -10 0 4 8 12 16 20 24 36 48 60 72 84 Placebo, week 84, -3.1% Placebo Metformin XR plus liraglutide, week 84, -7.2% Metformin XR plus liraglutide X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
-7.2% at week 84
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM) · NCT01234649
Dose n/r · n/r
Obesity + T2D
Y axis: Change in body weight from baseline, %
10 5 0 0 4 8 12 16 20 24 36 Placebo, week 32, 1.4% Placebo Liraglutide Pen Injector (Saxenda), week 32, 5.7% Liraglutide Pen Injector (Saxenda) X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
5.7% at week 32
SAXAPCOS · NCT03480022
16 mg · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
100 90 80 70 60 50 40 30 20 10 0 0 4 8 12 16 20 24 36 Placebo, week 32, 23.97% Placebo 16 mg Mazdutide, week 32, 92.23% 16 mg Mazdutide X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
92.23% at week 32
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight · NCT06124807
Dose n/r · n/r
Bardet Biedl Syndrome (BBS); Alström Syndrome...
Y axis: Change in body weight from baseline, %
0 -5 -10 0 4 8 12 16 20 24 36 48 60 Pivotal Cohort, week 52, -5.21% Pivotal Cohort X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
-5.21% at week 52
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity · NCT03746522
Dose n/r · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
0 -5 -10 -15 0 4 8 12 16 20 24 36 48 60 Setmelanotide, week 52, -12.34% Setmelanotide X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
-12.34% at week 52
Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity · NCT03287960
Dose n/r · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
0 -5 -10 -15 -20 -25 -30 0 4 8 12 16 20 24 36 48 60 Setmelanotide, week 52, -25.83% Setmelanotide X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
-25.83% at week 52
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity · NCT02896192
Dose n/r · n/r
Obesity or overweight
Y axis: Change in body weight from baseline, %
0 -5 0 4 8 12 16 20 24 Stage 1: Setmelanotide (Open-Label), week 16, -3.94% Stage 1: Setmelanotide (Open-Label) X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
One reported week is a point. It is not a line from 0%.
-3.94% at week 16
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway · NCT04963231